DaVita stock slips after Q2 revenue beats forecasts
Published on 08/19/2026 at 14:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
DaVita Inc. (US23918K1088) is weighing a Q2 2026 report that showed $3.55 billion in revenue and $4.02 in adjusted EPS, while the stock closed at $176.70 on August 18, 2026.
The quarter beat consensus EPS by $0.14, and revenue was up 5.2% year over year, but the shares still ended the session 1.87% lower at the close.
Q2 numbers stay in view
The latest quarter remains the main reference point. MarketBeat said DaVita posted its quarterly earnings on August 4, 2026, and the company reported $4.02 in EPS versus $3.88 expected, with quarterly revenue up 5.2% from a year earlier.
That mix matters because the stock also trades with a market cap of $11.36 billion and a trailing P/E of 15.27, which keeps valuation part of the debate as investors digest the earnings print.
Analysts keep talking
Analyst attention is still active, with a consensus price target of $221.75 and a consensus rating of Hold. The same data set shows 7 research reports in the past 90 days and a recent TD Cowen upgrade to Buy on August 7, 2026 with a target move from $201 to $220.
The comparison is concrete: the average target sits $45.05 above the August 18 close, while the high target reaches $270.00. That gap helps explain why the shares can react to each earnings update without losing analyst support.
Kidney care scale
DaVita's core business remains kidney care, including outpatient dialysis centers, home dialysis and related laboratory services. The company says it employs 78,000 people and operates from Denver, Colorado.
The business scale is the product story behind the numbers: a large dialysis network with recurring patient demand and a reimbursement model that keeps revenue tied to treatment volume, payer mix and operating discipline.
Trading setup
DaVita stock was quoted at $176.70 on August 18, 2026, with a day range of $176.20 to $180.00, a 52-week range of $101.00 to $247.49 and volume of 373,109 shares.
For now, the price sits well above the 52-week low and below the 52-week high, while the market waits for the next catalyst around the October 28, 2026 earnings date.
More on DaVita Inc.
DaVita's dialysis platform includes in-center hemodialysis, home therapies, vascular access support and lab services. That mix gives investors a direct read on treatment volume trends and reimbursement pressure.
DaVita stock and market data
As of August 18, 2026, DaVita stock closed at $176.70 on the NYSE, with a market cap of $11.36 billion.
Company
Company: DaVita Inc.
ISIN: US23918K1088
Ticker: DVA
Exchange: NYSE
Price (as of August 18, 2026, 4:00 p.m. ET): $176.70 USD
Market cap: $11.36 billion (as of August 18, 2026)
Sector / Industry: Healthcare / Healthcare Providers & Services
Index membership: S&P 500
Picture note
DaVita dialysis center and stock chart.
